Merck Announces Further Restructuring, Job Cuts - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Merck Announces Further Restructuring, Job Cuts


ePT--the Electronic Newsletter of Pharmaceutical Technology

Last week, Merck & Co. unveiled plans to reduce its global workforce, as measured by year-end 2009 levels, by an additional 12–13% by 2015. The company described its plans in its report on second-quarter earnings, which the company issued on July 29, 2011.

“Merck is taking these difficult actions so that we can grow profitably and continue to deliver on our mission well into the future,” said Kenneth Frazier, the company’s CEO and president, in a company statement. “The environment we operate in is changing rapidly and dramatically, and these steps will help us more efficiently serve customers and patients around the world.”

The latest round of job cuts is part of the next phase of an ongoing merger-restructuring program following the company’s merger with Schering-Plough in November 2009. Merck began its merger-restructuring program in February 2010 with the goal of reducing its total workforce. Through Dec. 31, 2010, the company eliminated 11,550 positions under the program, which included actual headcount reductions and the elimination of contractors and vacant positions, according to the company’s 2010 annual filing with the US Securities and Exchange Commission. As of June 30, 2011, Merck had approximately 91,000 employees, according to the company’s second-quarter 2011 earnings release.

Merck remains on track to achieve its goal of $3.5 billion in annual cost synergies by the end of 2012. By the end of 2015, Merck expects the overall merger-restructuring program to yield annual ongoing savings of $4.0 billion to $4.6 billion, which is more than its original estimate of $2.7 billion to $3.1 billion. Total cumulative pretax costs for the program are estimated to range between $5.8 billion and $6.6 billion.

The company did not specify in what areas it would eliminate jobs. But the company will continue to hire new employees in strategic growth areas such as emerging markets.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here